MedPal AI plc (AIM: MPAL) has highlighted the potential expansion of the GLP-1 market after the US Food and Drug Administration approved Eli Lilly’s Mounjaro to reduce the risk of
Avacta Awards CEO 13.4m Share Options at 69p as Clinical Pipeline Advances
Avacta (AIM: AVCT) has granted a substantial package of share options to its management team, including 13.4 million options to chief executive Christina Coughlin, as part of an incentive and
GENinCode Shares Jump 23% as CARDIO inCode Study Shows Improved Coronary Risk Prediction
GENinCode Plc (AIM: GENI) shares rose around 23% in early trading after the predictive genetics company reported encouraging clinical results for its CARDIO inCode-Score® test in the prevention of coronary
Nuformix Appoints Tim Metcalfe as Non-Executive Chairman
Nuformix plc (LON: NFX) has appointed Tim Metcalfe as Non-Executive Chairman, with the role taking effect from 1 September 2026.
Nuformix Reports Positive NXP002 Inhalation Study Results
Nuformix plc (LON: NFX) has reported positive preclinical results for NXP002, its potential inhaled treatment for idiopathic pulmonary fibrosis and other progressive fibrosing lung diseases.
MedPal highlights new UK oral weight-loss treatment
MedPal AI plc (AIM: MPAL) has highlighted the UK approval of Eli Lilly’s once-daily oral GLP-1 treatment, Foundayo, which has been authorised for weight loss and weight maintenance in eligible
BSF Enterprise Signs Exclusive Global ETSYL® Skincare Commercialisation Deal
BSF Enterprise PLC (LON: BSFA) has signed heads of terms with SCHAKAU Managementberatung GmbH for the worldwide exclusive commercialisation of its proprietary bioactive peptide ETSYL® across cosmetics, skincare, dermocosmetics and
ValiRx Secures Second European Patent for Cytolytix Cancer-Killing Peptide
ValiRx PLC (AIM: VAL) has received notice that the European Patent Office intends to grant a second patent covering the cancer-killing peptide being developed by its majority-owned subsidiary Cytolytix.
ImmuPharma Appoints Kymos Group to Support Kapiglucagon Development
ImmuPharma plc (AIM: IMM) has appointed Kymos Group as its bioanalytical contract research organisation partner for the development of Kapiglucagon, its proprietary glucagon prodrug for Type 1 diabetes applications.
Oxford Biomedica revenues rise as new client wins hit record
Oxford Biomedica (LON: OXB) has lowered its full-year 2026 revenue and profitability guidance after changes in customer ordering patterns and delays at its US facility, despite reporting record new client activity
MedPal AI Connects Pharmacy, Private Care and Software in a Rapid Growth Strategy
MedPal’s (AIM: MPAL) July trading update gave investors the clearest indication yet that its digital-health ambitions are being supported by real operating revenue. The company reported an annualised recurring revenue
Wellnex Life Shares Surge 84% on A$21.3 Million Pain Away Sale
Wellnex Life Limited (ASX/AIM: WNX) topped the market leaderboard after its shares surged 84% following the announcement of a binding agreement to sell its Pain Away business to Mentholatum Australasia for